Logo-bi
BioImpacts. 2022;12(3): 291-292. doi: 10.34172/bi.2022.23266
PMID: 35677665        PMCID: PMC9124879

Perspective

SARS-CoV-2 and probable lung cancer risk

Sajad Khiali 1 ORCID, Afra Rezagholizadeh 1 ORCID, Taher Entezari-Maleki 1,2 * ORCID

Cited by CrossRef: 5


1- Li S, Du Z, Ma H, Cai L, Liu X, He J. Mendelian randomization provides causal association between COVID-19 and thyroid cancer: insights from a multi-cancer analysis. Front Oncol. 2024;14 [Crossref]
2- Zeitlmayr S, Cami D, Selmani B, Gudermann T, Breit A. A dual role for ERK-1/2 in the regulation of plasmin activity and cell migration in metastatic NSCLC-H1299 cells. Arch Toxicol. 2023;97(12):3113 [Crossref]
3- Petersen E, Chudakova D, Erdyneeva D, Zorigt D, Shabalina E, Karalkin P, Reshetov I. Cancer as a potential sequela of COVID-19 — should we modify 3D cell culture models accordingly?. BioComm. 2023;68(3) [Crossref]
4- Alqaissi E, Alotaibi F, Sher Ramzan M, Algarni A. Novel graph-based machine-learning technique for viral infectious diseases: application to influenza and hepatitis diseases. Annals of Medicine. 2023;55(2) [Crossref]
5- Xian J, Huang H, Huang G, Zhou R, Yang M, Qiu Y, Bi L, Su Z, Xiao F, Shan H, Jin H. A Positron Emission Tomography Tracer Targeting the S2 Subunit of SARS-CoV-2 in Extrapulmonary Infections. Mol Pharmaceutics. 2022;19(11):4264 [Crossref]


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge